Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
171.08B
Market cap171.08B
Price-Earnings ratio
40.28
Price-Earnings ratio40.28
Dividend yield
5.65%
Dividend yield5.65%
Average volume
27.57M
Average volume27.57M
High today
$30.32
High today$30.32
Low today
$29.81
Low today$29.81
Open price
$30.32
Open price$30.32
Volume
29.48M
Volume29.48M
52 Week high
$30.44
52 Week high$30.44
52 Week low
$23.62
52 Week low$23.62

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $30.02. The company's market cap stands at 171.08B, with a P/E ratio of 40.28 and a dividend yield of 5.65%.

During the trading session on 2026-10-23, Pfizer(PFE) shares reached a daily high of $30.32 and a low of $29.81. At a current price of $30.02, the stock is +0.7% higher than the low and still -1.0% under the high.

Trading activity shows a volume of 29.48M, compared to an average daily volume of 27.57M.

The stock's 52-week range extends from a low of $23.62 to a high of $30.44.

The stock's 52-week range extends from a low of $23.62 to a high of $30.44.

PFE News

Simply Wall St 59m
Pfizer Showcases IDWeek Data, Is The Stock Fully Priced?

Advertisement Recent IDWeek data keeps Pfizer’s infectious disease engine in focus Pfizer (PFE) is putting its infectious disease research front and center, p...

24/7 Wall St. 10h
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Investing Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip Full late-stage results for the personalized melanoma vac...

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Simply Wall St 1d
Pfizer And 2 Other AI Healthcare Stocks To Own

Nvidia CEO Jensen Huang says demand for AI computing is “off the charts” even as investors question the huge bill for data centers and chips. That tension betwe...

Pfizer And 2 Other AI Healthcare Stocks To Own

Analyst ratings

62%

of 29 ratings
Buy
27.6%
Hold
62.1%
Sell
10.3%

More PFE News

The Motley Fool 1d
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue

Bristol Myers Squibb: A Steady Upward Revenue Trend Bristol Myers Squibb (BMY +3.08%) primarily generates revenue by developing and selling prescription medicin...

Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
24/7 Wall St. 1d
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher

Investing Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher A melanoma vaccine report appeared online,...

Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
TipRanks 1d
Pfizer Targets Eczema Market Upside With New Phase 3 Tilrekimig Trial

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is advancing a late-stage study testing tilrekimig for people 12 and ol...

TipRanks 1d
Pfizer’s Swedish Ibrance Study Offers Fresh Real‑World Signals for PFE Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study. The Swedish Ibrance Registries Insights (SIRI) study looks at how Pfizer’s palbociclib is...

TipRanks 1d
Pfizer’s PF-07999415 Trial Reaches Phase 1 Finish Line, Offering Fresh Clues for Pipeline Value

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) has completed a Phase 1 study called “A Study to Learn How Different Am...

24/7 Wall St. 1d
Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares

Investing Pfizer’s High Dividend Yield May Be a Warning. Here’s How Merck Compares Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal som...

Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares
Simply Wall St 2d
Pfizer Backs Sec61 Drug Hunt In New Research Collaboration

Pfizer (NYSE:PFE) entered a research collaboration with Enodia Therapeutics to discover and develop small‑molecule Sec61 inhibitors. The agreement gives Pfizer...

Pfizer Backs Sec61 Drug Hunt In New Research Collaboration

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.